Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.68 |
| ▸ | PKM | P14618 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | ABL1 | P00519 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | IDE | P14735 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.68 |
| ▸ | F2 | P00734 | 1/20 | 0.62 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.62 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.62 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.62 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.62 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16123471 | 1.00 | TDP1 (0.68) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL23334534 | 1.00 | TDP1 (0.68) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL22769273 | 0.97 | FOLH1 (0.69) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL30504309 | 0.96 | FOLH1 (0.70) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL13185305 | 0.94 | FOLH1 (0.63) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL18957487 | 0.93 | TDP1 (0.66) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL8131388 | 0.93 | FOLH1 (0.71) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL26902897 | 0.92 | TDP1 (0.62) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL14795037 | 0.92 | TDP1 (0.62) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL13791515 | 0.91 | FOLH1 (0.62) | TDP1PKMMEN1ABL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383914-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-21 | — | — | US | disclosed |
| US-12065446-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-20 | — | — | US | disclosed |
| US-20230097422-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | US | disclosed |
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| US-11319329-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| US-20220009916-A1 | ACETYLATION WRITER INHIBITOR DEVELOPMENT AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-01-13 | — | — | US | disclosed |
| US-11053197-B2 | Carbazole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| US-20210101910-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-08 | — | — | US | disclosed |
| US-10934310-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-02 | — | — | US | disclosed |
| US-10822348-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-03 | — | — | US | disclosed |
| US-20170029442-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. | 2017-02-02 | — | — | US | disclosed |
| US-9504686-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9464089-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-03-24 | — | — | US | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-9145387-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150133457-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA BIOSCIENCES INC. | 2015-05-14 | — | — | US | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| WO-2014124230-A2 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934310-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | TDP1 239/4885PKM 1330/4885MEN1 2524/4885 |
| US-12065446-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | TDP1 239/4885PKM 1330/4885MEN1 2524/4885 |
| US-20170029442-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BMX, BLK, BTK | TDP1 1300/4885PKM 1046/4885MEN1 3389/4885 |
| US-20150133457-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BMX, BLK, BTK | TDP1 1300/4885PKM 1046/4885MEN1 3389/4885 |
| US-11542492-B2 | Ligand-directed covalent modification of protein | PTMS, SPR, DNPEP | TDP1 2588/4885PKM 1299/4885MEN1 4479/4885 |
| US-20240383914-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | ABL1, BTK, MYLK2 | TDP1 198/4885PKM 1419/4885MEN1 2475/4885 |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | MAPK1, MAPK3, MAP4K2 | TDP1 2480/4885PKM 1283/4885MEN1 1944/4885 |
| US-20230097422-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, LYN | TDP1 239/4885PKM 1330/4885MEN1 2524/4885 |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | PTMS, SPR, DNPEP | TDP1 2588/4885PKM 1299/4885MEN1 4479/4885 |
| US-10822348-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | ABL1, BTK, MYLK2 | TDP1 193/4885PKM 1466/4885MEN1 2461/4885 |
| US-20210101910-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | ABL1, BTK, MYLK2 | TDP1 198/4885PKM 1419/4885MEN1 2475/4885 |
| US-11053197-B2 | Carbazole derivatives | BTK, SYK, JAK2 | TDP1 329/4885PKM 3533/4885MEN1 2662/4885 |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | TDP1 2390/4885PKM 944/4885MEN1 2133/4885 |
| US-20220009916-A1 | ACETYLATION WRITER INHIBITOR DEVELOPMENT AND USES THEREOF | EP300, KAT2A, HDAC2 | TDP1 1190/4885PKM 3004/4885MEN1 3780/4885 |
| US-11319329-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | ABL1, BTK, MYLK2 | TDP1 198/4885PKM 1419/4885MEN1 2475/4885 |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | TDP1 2390/4885PKM 944/4885MEN1 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.